Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904614 · ClinicalTrials.gov registry record · Phase 4
Letermovir Use in Heart Transplant Recipients
A Phase 4 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT04904614 is a Phase 4 study that has completed, run by Tufts Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT04904614, a Phase 4 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus. The study will compare a 30 patient prospective cohort to a retrospective cohort of 374 heart transplant recipients for the rates of neutropenia. In addition, the tolerability of letermovir will be assessed in this population.
Interventions
- DRUG Letermovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2025-01-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904614
The ClinicalTrials.gov registry entry for NCT04904614 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letermovir is the first listed.
NCT04904614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04904614 about?
NCT04904614 is a clinical study titled "Letermovir Use in Heart Transplant Recipients". This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus. The study will compare a 30 patient prospective cohort to a retrospective cohort of 374 heart t...
What is the current status of trial NCT04904614?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2022-01-05. Estimated completion is 2025-01-14.
What interventions are being tested in trial NCT04904614?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT04904614?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.